These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 27296819

  • 1. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
    Donohue JF, Soong W, Wu X, Shrestha P, Lei A.
    Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF, AUGMENT COPD study investigators.
    Respir Res; 2014 Oct 14; 15(1):123. PubMed ID: 25756831
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
    Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Gil EG, Leselbaum A.
    BMC Pulm Med; 2014 Nov 18; 14():178. PubMed ID: 25404569
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M, Chapman KR, Chuecos F, Ribera A, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2016 Nov 18; 11():2041-53. PubMed ID: 27621610
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
    D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Gil EG.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 18; 14():479-491. PubMed ID: 30880938
    [Abstract] [Full Text] [Related]

  • 11. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
    Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C, LAS-MD-35 study investigators.
    Respir Med; 2013 Dec 18; 107(12):1957-65. PubMed ID: 23916502
    [Abstract] [Full Text] [Related]

  • 12. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ.
    Adv Ther; 2019 Sep 18; 36(9):2434-2449. PubMed ID: 31267366
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.
    Respir Med; 2017 May 18; 126():105-115. PubMed ID: 28427541
    [Abstract] [Full Text] [Related]

  • 14. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
    Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E.
    Int J Chron Obstruct Pulmon Dis; 2017 May 18; 12():2545-2558. PubMed ID: 28883722
    [Abstract] [Full Text] [Related]

  • 15. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
    Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E.
    Int J Chron Obstruct Pulmon Dis; 2019 May 18; 14():667-682. PubMed ID: 30962681
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.
    Respir Med; 2016 Nov 18; 120():16-24. PubMed ID: 27817811
    [Abstract] [Full Text] [Related]

  • 18. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z, TRIDENT study investigators.
    Respir Med; 2016 May 18; 114():84-90. PubMed ID: 27109816
    [Abstract] [Full Text] [Related]

  • 19. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 May 18; 15():99-106. PubMed ID: 32021148
    [Abstract] [Full Text] [Related]

  • 20. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R, Zhong N, Wang HY, Zhao L, Mei X, Qin Z, Huang J, Assam PN, Maes A, Siddiqui S, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020 May 18; 15():43-56. PubMed ID: 32021143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.